
Edison
Oryzon Genomics has reported its Q126 results, reflecting a productive period for the company. Notably, Oryzon is executing its strategy involving a higher focus on iadademstat in oncology/haematology...

Edison
Oryzon Genomics has announced updated positive data from two iadademstat acute myeloid leukaemia (AML) studies to be presented at EHA 2026, further strengthening the clinical rationale for its LSD1 in...